Ghandehari Kavian
Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, P.O. Box: 91766-99199, Iran.
Stroke Res Treat. 2011;2011:686797. doi: 10.4061/2011/686797. Epub 2011 Mar 17.
The developing world carries the highest burden of stroke mortality and stroke-related disability. The number of stroke patients receiving r-tPA in the developing world is extremely low. Prehospital delay, financial constraints, and lack of infrastructure are main barriers of thrombolysis therapy in developing countries. Until a cheaper thrombolytic agent and the proper infrastructure for utilization of thrombolytic therapy is available, developing countries should focus on primary and secondary stroke prevention strategies. However, governments and health systems of developing countries should efforts exerb for promotion of their infrastructure of stroke care.
发展中世界承受着中风死亡率和与中风相关残疾的最高负担。在发展中世界，接受重组组织型纤溶酶原激活剂（r-tPA）治疗的中风患者数量极低。院前延误、资金限制和基础设施匮乏是发展中国家溶栓治疗的主要障碍。在有更便宜的溶栓药物以及利用溶栓治疗的适当基础设施之前，发展中国家应专注于中风的一级和二级预防策略。然而，发展中国家的政府和卫生系统应努力改善其中风护理基础设施。
